Sending Office: Honorable Sanford D. Bishop, Jr.
Prostate Cancer deaths are on the rise!
Please help us continue needed Prostate Cancer research
DEADLINE: Friday, March 6th
Please join us in writing the House Appropriations Committee to express your support for the Prostate Cancer Research Program (PCRP) within the Department of Defense (DoD). Prostate cancer is the most common cancer diagnosed in men and is the second leading
cause of cancer deaths among men. One in nine men will be diagnosed in their lifetimes, and 3.1 million men are living with a prostate cancer diagnosis today.
An estimated over 190,000 men will be diagnosed with prostate cancer in 2020. But what is more disturbing is more than 33,000 men are expected to die in 2020 from prostate cancer – an increase of more than 2,000 deaths than in 2019 and over 7,000 more deaths
than in 2017!
In the African-American population the numbers are even more grim. African-American men are 74 percent more likely to develop prostate cancer than Caucasian men and twice as likely to die.
We can stop these trends with the help of targeted research.
The attached letter to the Appropriations Committee requests $110 million for the PCRP in Fiscal Year (FY) 2021, which represents level funding compared to FY2020.
We appreciate your support in this vital effort to save men’s lives and support important scientific breakthroughs. Please contact Jonathan Halpern in Rep. Sanford Bishop’s office at firstname.lastname@example.org or Deena Tauster in Rep. Peter King’s office
at email@example.com by Friday, March 6th for more information or to sign-on.
Representative Sanford D. Bishop, Jr. Representative Peter T. King
March 16, 2019
The Honorable Peter Visclosky The Honorable Ken Calvert
Chairman Ranking Member
Subcommittee on Defense Subcommittee on Defense
House Appropriations Committee House Appropriations Committee
H-405, The Capitol 1016 Longworth House Office Building
Washington, DC 20515 Washington, DC 20515
Dear Chairman Visclosky and Ranking Member Calvert:
This year, over 190,000 men will be diagnosed with prostate cancer, and it is estimated that more than 33,000 men will die from this disease. As you consider the Fiscal Year (FY) 2021 Defense Appropriations Act, we respectfully request that the Committee
appropriate $110 million to the Department of Defense’s (DOD’s) Prostate Cancer Research Program (PCRP).
After more than two decades of decreasing prostate cancer rates, prostate cancer deaths are now on the rise. When caught early, prostate cancer has a nearly one hundred percent five-year survival rate. When the disease has metastasized, the survival rate
drops to 30 percent. It is estimated that 2,000 more men will die this year than in 2019 of prostate cancer. And that number reflects an increase of 7,000 more deaths when compared to 2017. Now more than ever we need research to better treat and diagnose
Since 1996, the Committee has been instrumental in advancing prostate cancer research by funding the DOD’s Congressionally Directed Medical Research Program (CDMRP) for prostate cancer. Its administrative structure has demonstrated an ability to be flexible
and quickly adjust responses to changing medical research needs and priorities. The PCRP, which compliments larger NIH basic science efforts, is the gold standard in prostate cancer research and an integral weapon in the national fight against prostate cancer.
Unlike the NIH, PCRP has clear priorities each year that target gaps in prostate cancer diagnostics, care, and treatment with an emphasis on meeting the needs of the prostate cancer community. The programmatic review of all proposals ensures that the government
is not spending scarce dollars on duplicative research. This structure works. In the last nine years, the PCRP has produced three new treatments for metastatic prostate cancer and one new advanced diagnostic.
Not only is the PCRP effective, it is military relevant. Prostate cancer is the most frequently diagnosed cancer among male veterans. Active duty men have an incidence rate that is twice that of the general population. Between 2005 and 2014, prostate cancer
accounted for 11.7 percent of cancer diagnoses in active duty men. In addition, it is well known that cancer diagnoses among service members as well as their families have a negative impact on psychological health and military readiness.
For these reasons, we request a FY2021 appropriation of $110 million for the PCRP within the CDMRP, which is equal to the FY2020 level. Researchers will use this funding to: develop treatments that improve outcomes for men with lethal prostate cancer; reduce
lethal prostate cancer in African Americans, Veterans, and other high-risk populations; define the biology of lethal prostate cancer to reduce death; and improve the quality of life for survivors of prostate cancer.
Please join us in making prostate cancer research, awareness and early detection a national health care priority by ensuring that adequate resources are available for the DOD PCRP. We recognize the difficult task ahead of your subcommittee in setting priorities
among the many needs of our nation but we greatly appreciate your consideration of this request.
e-Dear Colleague version 2.0